pneumococcal polysaccharide vaccine + pneumococcal conjugate vaccine

This is a sequential vaccination strategy that combines pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23) with a pneumococcal conjugate vaccine (PCV, such as Prevnar 13, Prevnar 20, or other PCVs). The rationale for sequential administration is to provide broader protection against pneumococcal disease. Studies have shown that administering the pneumococcal conjugate vaccine first leads to a better immune response to serotypes common to both vaccines when the polysaccharide vaccine is given later. The recommended interval between the two vaccines varies based on age and risk factors, typically being 1 year for most adults, but can be shortened to 8 weeks for immunocompromised individuals.

Brand names

Pneumovax 23 + Prevnar 13Pneumovax + PrevenarPNEUMOVAX 23 + Prevnar 20PNEUMOVAX 23 + PCV13PNEUMOVAX 23 + PCV15PNEUMOVAX 23 + PCV20PNEUMOVAX 23 + PCV21

Other names

PPSV23 + PCV13PPSV23 + PCV15PPSV23 + PCV20PPSV23 + PCV21